SGS's H3N2 influenza virus, which can be used for human challenge testing in our Belgium viral clinical pharmacology unit, has received The Medicine Maker journal's 2017 Innovation Award.

The award, now in its third year, celebrates the most exciting technologies and techniques used in the creation of new pharmaceutical and biopharmaceutical products.

During the nomination period for the 2017 award, a record number of entries were received from companies around the globe. The H3N2 challenge virus was one of only 15 winners.

Learn more about the winners >

Readers are invited to vote for one of the winners to be featured in a 2018 article in the journal.

Vote for us here >

For further information, please contact:

Florent Hediard
Life Sciences, Clinical Research - Marketing Director
Agriculture, Food and Life
t: +33 (0) 1 41 24 84 95
www.sgs.com/lifescience
www.sgs.com/linkedin-life

SGS is the world's leading inspection, verification, testing and certification company. SGS is recognized as the global benchmark for quality and integrity. With more than 90,000 employees, SGS operates a network of over 2,000 offices and laboratories around the world.

SGS SA published this content on 05 January 2018 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 05 January 2018 08:39:03 UTC.

Original documenthttp://www.sgs.com/en/news/2018/01/sgs-h3n2-challenge-virus-receives-the-medicine-maker-innovation-award

Public permalinkhttp://www.publicnow.com/view/5690816FA31732F0CCEE32C3F65B9BB19FF3CF64